Igf2-cKO mice treated with anti–PD-1 demonstrated the most effective tumor retardation, significantly prolonged survival, and exhibited increased infiltration of T cells, along with enhanced antitumor activity of CD8+ T cells compared with WT mice treated with anti–PD-1 (Figure 6, D–G). The gene discussed is CD8A; the disease is neoplasm.